VistaGen's Singh says partnerships in large markets outside U.S. make most sense
VistaGen Therapeutics (VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system diseases and disorders with high unmet need. In an exclusive interview with The Fly, the company's CEO Shawn Singh discussed potential partnerships: "We are always open to collaborative relationships that enhance our potential to achieve optimal commercial benefits from our product candidates and thereby deliver extraordinary value to patients and our shareholders. In certain large and growing markets outside North America, such as China and Japan, and possibly the EU and Korea, partnering for Phase 3 development, and possibly some Phase 2 development, as well as commercialization of one or more of our product candidates may make the most sense strategically. We have been and certainly will continue exploring possibilities and interest from potential partners in parallel with our ongoing and planned clinical development activities in the U.S." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.